Tags: Keywords: Competition Commission of India (CCI) Pharmaceuticals, Market regulation, Consumer behavior, Anticompetitive practices
Downloads: 0
View: 27
At the very junction of public health lies the pharmaceutical sector. It is essential to examine the effects of regulations and market structure in line with competition law aspects. Therefore, this study aims to look into the extent and impact of the pharmaceutical sector practices and trends onto the consumers especially at a retail level in the Bengaluru region. How local market dynamics and regulatory weakness have led to price distortion and reduced access to medicine which overall harms an innocent and uninformed consumer. Using a mixed and interactive approach of combining empirically accessed and doctrinally analysed data to assess the impact on consumers. This study draws its conclusions from a structured survey of pharmacies and consumers, including 15 outlets and 35 consumers. The Competition Act of 2002 and the DPCO of 1995 along with landmark cases like Novartis AG v Union of India (2013) have been relied on. Additionally, reliance has been placed on Indias situation within the global discussion on pharmaceutical competition policy. The studies have revealed brand favoritism, entry barriers, and limiting of consumer choices. Significant gaps in the legal framework have been strawed out and inclusion of stronger enforcement measures by CCI is recommended for transparency.
Dr. Seema Shrivastava & Aarya Shrivastava (2026) "REGULATING MARKET POWER: AN EMPIRICAL AND LEGAL ANALYSIS OF ANTICOMPETITIVE PRACTICES IN INDIAS PHARMACEUTICAL SECTOR", GNLU Journal of Law And Economics : Volume VIII 2025, Issue II
Available at:
https://gnlu.ac.in/GJLE/Publications/REGULATING MARKET POWER: AN EMPIRICAL AND LEGAL ANALYSIS OF ANTICOMPETITIVE PRACTICES IN INDIAS PHARMACEUTICAL SECTOR
In 2023, the Delhi High Court disposed of more than 87,000 cases, a recordbreaking figure. Yet its backlog grew. Across India, governments have doubled judicial strength in some states, built stateoftheart ecourts, and implemented case management software. Still, over 5.1 crore cases remain pending. The standard explanation treats this as a resource problem: too few judges chasing too many litigants. But what if the real answer is more uncomfortable What if delay is not a bug in the system, but a feature, a currency that judges spend, save, and strategically deploy This paper advances a heretical proposition: that for the Indian High Court judge, disposing of cases is not always the rational choice. In a system where the government is simultaneously the largest litigant and the arbiter of judicial careers, where a controversial judgment can trigger a punitive transfer while a safe adjournment goes unnoticed, and where forty dismissals at the admission stage count the same as one laboriously reasoned final verdict, delay emerges as the equilibrium strategy. The crisis of pending cases is not an accident of overload; it is the predictable outcome of incentives working exactly as designed. Employing a political economy framework, we model the High Court judge as a strategic actor maximizing a utility function comprised of reputation (professional prestige), leisure (workload aversion), promotion prospects (chances of elevation or postretirement appointment), and the cost of dissent (risk of punitive transfer or career backlash). The paper proposes an empirical model to test whether judicial delays correlate with political cycles and the identity of the litigant (State vs. Citizen), suggesting that strategic delay is a rational response to the institutional constraints of the Indian judiciary.